CTIBIOTECH

  • Home
  • Company
    • Mission
    • Key Points
    • Key Staff
    • Structural Partners
    • Public Engagement
    • Education
    • Recruitment
    • Laboratory
  • Technology
    • Cancer
    • IMODI
    • Adult Stem Cell Technology Platforms
    • In vitro tox & drug testing
    • Dermatocosmetics / Skin
    • Clinical trials development
    • Biobanking
    • Medical Device R&D
    • Strategic R&D Partners
  • Services
    • Products
      • Tissues and cells
      • Cancer cells
    • Contract testing
    • Medical device
    • Consultancy
    • Our Clients
    • IMODI Products
  • Investors / Media
    • Why we are different
    • News
    • Resources
    • Legal
  • 会社案内
    • 設立 主旨
    • 基盤技術
    • 実績
    • 提供するサービス
    • パートナー
    • 体制
    • 資本
    • パブリケーション
    • サポート
  • Contact

Medical device

CTIBIOTECH has had considerable success in medical device work, including in:
  • medical device developments, leading to the award of 2 CE marks
  • medical device development, specific for the USA market, leading to 2 FDA awards already passed and an additional FDA award in review
  • testing of biomaterials, leading to patented products

A case study appears below.


 

CaseStudyMedical device for rapid processing of Human Cord Blood, using no electricity

 

KanekaContracting company: KANEKA Corporation, Osaka, Japan. A company with a 5 billion dollar turnover (2014).

 

Schema of CellEffic CB
Schema of CellEffic CB

RESULT:     CellEffic CB product for processing umbilical cord blood developed. Two successful CE marks awarded. Trademarks awareded globally. Work published in abstracts and 2 peer-reviewed journal publications. Product on sale.

 

cb_celleffic_02-1

 

First Journal publication from the work:

A novel filtration method for cord blood processing using a polyester fabric filter.
Takahiro Shima, Nico Forraz, Nobuhiko Sato, Takuji Yamauchi, Tomoko Henzan, Katsuto Takenaka, Koichi Akashi, Colin McGuckin and Takanori Teshima.
International Journal of Laboratory Hematology, Dec 14.2012.
doi: 10.1111/ijlh.12039

Introduction:     Cord blood (CB) is being increasingly used as a source of hematopoietic stem cells for transplantation to treat diseases of the blood and immune systems, and there is an urgent need to expand CB banking worldwide. CB processing requires costly machinery or a clean room that hampers wider application of CBT particularly in the developing countries.

Methods:    We developed a novel filtration system using a nonchemical-coated and nonwoven polyester fabric filter, which traps cells through affinity and does not require centrifugation or potentially toxic chemicals.

Results:    Cell processing with the device resulted in minimum cell loss of total cells and CD34+cells, without impairing the ability of CD34+cells to engraft and differentiate both in vivo and in vitro.

Conclusion:    CB processing with this device is simple, cost-effective, and nontoxic without requiring costly equipment will thus facilitate international CB banking, which helps in meeting the increasing worldwide demand for CB for allogeneic hematopoietic stem cell transplantation.

Some of the patents covering the device (US version):
METHOD AND MATERIAL FOR SEPARATING LEUKOCYTES OR MONONUCLEAR CELLS
United States Patent Application 20130323712
An object of the present invention is to provide a separation system and a separation material for efficiently separating white blood cells or mononuclear cells from a biological fluid containing blood cell components. White blood cells or mononuclear cells can be efficiently separated by contacting a biological fluid containing blood cell components with a separation material having an average fiber diameter of at least 2.0 μm but not more than 6.0 μm and an air permeability coefficient M of at least 6.2 but not more than 35 to capture white blood cells on the separation material, and recovering the captured white blood cells or mononuclear cells using a detachment solution.
 
BLOOD COMPONENT SEPARATION SYSTEM AND SEPARATION MATERIAL
United States Patent Application 20120141975
The present invention relates to a separation system and a separation material for easily and rapidly separating a red blood cell-rich fraction, a white blood cell-rich fraction, and/or a platelet-rich fraction from a biological fluid containing these blood cell components without the necessity of performing centrifugation. The separation of a red blood cell-rich fraction, a white blood cell-rich fraction, and/or a platelet-rich fraction from a biological fluid can be accomplished by capturing white blood cells and platelets on a blood cell separation material by contacting the biological fluid with the blood cell separation material, thereby providing a red blood cell-rich fraction; and recovering a white blood cell-rich fraction by separating white blood cells captured from the resulting blood cell separation material using a separation solution.

 

COMPANY PROFILE

CTIBIOTECH aims to maximize the potential of tissues created by stem cell technologies and biopsies from cancer and skin for human therapeutic benefit

Read More

NEWS

Read about the latest CTIBIOTECH developments *LATEST* October 2016, CTIBIOTECH will be present in Japan for the BIOJAPAN international meeting

Read more here

SEARCH

Copyright © 2023 · CTIBIOTECH - All rights reserved. Log in